BR112014025058B1 - Combinação de análogos de somatostatina com inibidores de 11beta-hidroxilase, e seus usos - Google Patents

Combinação de análogos de somatostatina com inibidores de 11beta-hidroxilase, e seus usos Download PDF

Info

Publication number
BR112014025058B1
BR112014025058B1 BR112014025058-8A BR112014025058A BR112014025058B1 BR 112014025058 B1 BR112014025058 B1 BR 112014025058B1 BR 112014025058 A BR112014025058 A BR 112014025058A BR 112014025058 B1 BR112014025058 B1 BR 112014025058B1
Authority
BR
Brazil
Prior art keywords
combination
cushing
compound
syndrome
patients
Prior art date
Application number
BR112014025058-8A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014025058A2 (https=
Inventor
Germo Hans Gericke
Herbert Anton Schmid
Mario Roberto Lutomirsky Maldonado
Li Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014025058A2 publication Critical patent/BR112014025058A2/pt
Publication of BR112014025058B1 publication Critical patent/BR112014025058B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014025058-8A 2012-04-12 2013-04-10 Combinação de análogos de somatostatina com inibidores de 11beta-hidroxilase, e seus usos BR112014025058B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623117P 2012-04-12 2012-04-12
US61/623,117 2012-04-12
PCT/EP2013/057515 WO2013153129A1 (en) 2012-04-12 2013-04-10 Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors

Publications (2)

Publication Number Publication Date
BR112014025058A2 BR112014025058A2 (https=) 2017-06-20
BR112014025058B1 true BR112014025058B1 (pt) 2022-07-12

Family

ID=48289057

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014025058-8A BR112014025058B1 (pt) 2012-04-12 2013-04-10 Combinação de análogos de somatostatina com inibidores de 11beta-hidroxilase, e seus usos

Country Status (13)

Country Link
US (1) US9333234B2 (https=)
EP (1) EP2836228B1 (https=)
JP (1) JP6383352B2 (https=)
KR (1) KR102136214B1 (https=)
CN (1) CN104321074B (https=)
AU (1) AU2013246908B2 (https=)
BR (1) BR112014025058B1 (https=)
CA (1) CA2869442C (https=)
ES (1) ES2980806T3 (https=)
IN (1) IN2014DN09240A (https=)
MX (1) MX362533B (https=)
RU (1) RU2663455C2 (https=)
WO (1) WO2013153129A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041967T2 (hu) * 2010-01-14 2019-06-28 Novartis Ag Mellékvese hormon-módosító szer alkalmazása
PH12016502540B1 (en) 2014-07-07 2022-07-20 Recordati Ag Pharmaceutical dosage forms
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
JP6765443B2 (ja) * 2016-01-19 2020-10-07 コーセプト セラピューティクス， インコーポレイテッド 異所性クッシング症候群の鑑別診断

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521456A (ja) * 1998-07-30 2002-07-16 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス ソマトスタチン類似体の使用法
EP1397150A4 (en) * 2001-04-09 2005-01-26 Administrators Ofthe Tulane Ed Somatostatin agonists
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
ES2472446T3 (es) * 2009-11-30 2014-07-01 Novartis Ag Derivados de imidazol como inhibidores de aldosterona sintasa
HUE041967T2 (hu) * 2010-01-14 2019-06-28 Novartis Ag Mellékvese hormon-módosító szer alkalmazása
WO2013131879A1 (en) * 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide

Also Published As

Publication number Publication date
AU2013246908B2 (en) 2016-06-30
BR112014025058A2 (https=) 2017-06-20
CN104321074B (zh) 2017-09-08
JP2015512923A (ja) 2015-04-30
JP6383352B2 (ja) 2018-08-29
US20150087588A1 (en) 2015-03-26
WO2013153129A1 (en) 2013-10-17
CN104321074A (zh) 2015-01-28
KR20150004831A (ko) 2015-01-13
AU2013246908A1 (en) 2014-10-23
ES2980806T3 (es) 2024-10-03
KR102136214B1 (ko) 2020-07-22
RU2663455C2 (ru) 2018-08-06
MX2014012321A (es) 2015-09-24
EP2836228B1 (en) 2024-03-20
EP2836228A1 (en) 2015-02-18
IN2014DN09240A (https=) 2015-07-10
CA2869442C (en) 2020-09-08
RU2014145351A (ru) 2016-06-10
MX362533B (es) 2019-01-23
US9333234B2 (en) 2016-05-10
CA2869442A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
Virdis et al. Human ghrelin: a gastric hormone with cardiovascular properties
BR112013018679B1 (pt) Agente para o tratamento da alopecia e uso de um peptídeo natriurético do tipo c
CN113288887A (zh) 用于治疗癌症的方法
US10835506B2 (en) Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
Pivonello et al. The dopaminergic control of Cushing’s syndrome
AU2019405771B2 (en) Methods for imaging and treatment of somatostatin-receptor positive tumors
BR112014025058B1 (pt) Combinação de análogos de somatostatina com inibidores de 11beta-hidroxilase, e seus usos
JP2017522389A (ja) シス−クロミフェンを用いたアンドロゲン除去療法によって生じるホットフラッシュ及び骨量減少の治療
Kannan The pituitary gland
CN1168448C (zh) 预防和/或治疗乳腺癌的含类固醇芳香酶抑制剂的药物
Gozes et al. Potential clinical applications of vasoactive intestinal peptide: a selected update
US9682066B2 (en) Methods of treating primary brain tumors by administering letrozole
Rieu et al. Paradoxical effect of somatostatin analogues on the ectopic secretion of corticotropin in two cases of small cell lung carcinoma
CA3122581C (en) Methods for imaging and treatment of somatostatin-receptor positive tumors
Szylberg et al. Oxytocin and its role and effects-recent findings
Zotarelli Filho State-of-the-Art Clinical Results of Growth Hormone Secretagogues, SARM and Antagonists
WO2025117962A1 (en) Compositions and methods for treating glucose-dependent insulinotropic peptide-dependent cushing's syndrome
JP2008127377A (ja) Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。
US20090062246A1 (en) Therapeutic treatment-014
Schlechte of Hyperprolactinemia
Kannan Central Hypothyroidism—Trophoprivic Hypothyroidism
WO2013033432A1 (en) Methods and compositions for treating type 2 diabetes and related conditions

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/04/2013, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.